XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access
via the World Wide Web to its presentation at the Piper Jaffray Fourth
Annual Europe Conference. The live presentation will occur at 5:00 a.m.
Pacific Daylight Time (12:00 p.m. GMT) on Tuesday, June 23, 2009. A
replay of the presentation will also be available.
To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Web site at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may
be necessary to listen to the Webcast.
A replay of the Webcast can be accessed for a minimum of one month and
will be available approximately 24 hours after the live presentation.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a
portfolio of internally discovered product candidates that utilize the
body’s natural nutrient transport mechanisms to improve the therapeutic
benefits of existing drugs. XenoPort is developing XP13512, its lead
product candidate, in collaboration with Astellas Pharma Inc. and
GlaxoSmithKline (GSK). The U.S. Food and Drug Administration is
currently reviewing the new drug application filed by GSK for XP13512 as
a potential treatment for moderate-to-severe primary restless legs
syndrome. In addition, XenoPort’s product candidates are being studied
for the potential treatment of neuropathic pain, migraine headaches,
gastroesophageal reflux disease, spasticity related to spinal cord
injury, acute back spasms and Parkinson’s disease.
To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
XenoPort is a registered trademark.
XNPT2G
XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
